title: Remission makes its way to rheumatology.
abstract: Remission was a rare event, even in the most advanced rheumatology clinics, until recent times. However, in the early 1990s, it was chosen as the treatment goal and the primary outcome measure for the Finnish Rheumatoid Arthritis Combination Therapy (FIN-RACo) trial, which can be considered the beginning of remission's way to rheumatology. In addition to remission in patients with rheumatoid arthritis, remission in patients with psoriatic arthritis is now being studied, although remission criteria for psoriatic arthritis have yet to be defined. Better treatment results with more active treatment strategies and availability of biologic agents motivate rheumatologists to monitor their patients as part of usual rheumatology care.
authors.forename: Tuulikki
authors.initials: T
authors.lastname: Sokka
authors.forename: Heidi
authors.initials: H
authors.lastname: Mäkinen
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D006801:Humans; D012074:Remission Induction; D012219:Rheumatology / Q000639:trends*
chemical_list: D018501:Antirheumatic Agents